Apellis Pharmaceuticals Inc (APLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 1,003,782 | 781,367 | 396,591 | 75,422 | 66,563 |
| Cost of Goods | 102,236 | 117,723 | 58,510 | 5,636 | 80,200 |
| Gross Profit | 901,546 | 663,644 | 338,081 | 69,786 | -13,637 |
| Operating Expenses | 846,355 | 829,346 | 855,712 | 665,035 | 522,840 |
| Operating Income | 55,427 | -164,979 | -517,121 | -594,613 | -536,277 |
| Interest Expense | 44,327 | 40,391 | 29,581 | 32,626 | 13,241 |
| Other Income | 13,010 | 8,654 | 20,206 | -24,264 | -196,484 |
| Pre-tax Income | 24,110 | -196,716 | -526,496 | -651,503 | -746,002 |
| Income Tax | 1,722 | 1,162 | 2,132 | 669 | 352 |
| Net Income Continuous | 22,388 | -197,878 | -528,628 | -652,172 | -746,354 |
| Net Income | $22,388 | $-197,878 | $-528,628 | $-652,172 | $-746,354 |
| EPS Basic Total Ops | 0.18 | -1.60 | -4.45 | -6.15 | -8.84 |
| EPS Basic Continuous Ops | 0.18 | -1.60 | -4.45 | -6.15 | -8.84 |
| EPS Diluted Total Ops | 0.20 | -1.60 | -4.45 | -6.15 | -8.84 |
| EPS Diluted Continuous Ops | 0.17 | -1.60 | -4.45 | -6.15 | -8.84 |
| EPS Diluted Before Non-Recurring Items | 0.20 | -1.58 | -4.45 | -6.15 | -8.84 |
| EBITDA(a) | $59,481 | $-161,623 | $-515,040 | $-565,685 | $-532,629 |